PRV (Priority Review Voucher)

PARIS, FRANCE: Valneva SE, a company that specializes in vaccines, has sold a PRV (Priority Review Voucher) received from the U.S. FDA (Food and Drug Administration) for €95 million ($103 million). The PRV was given to Valneva in November 20231 after the U.S. FDA approved its chikungunya vaccine, IXCHIQ®, which is the first of its…